Haemonetics Statistics
Total Valuation
Haemonetics has a market cap or net worth of $3.53 billion. The enterprise value is $4.45 billion.
Important Dates
The last earnings date was Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Haemonetics has 50.24 million shares outstanding. The number of shares has decreased by -1.30% in one year.
| Current Share Class | 50.24M |
| Shares Outstanding | 50.24M |
| Shares Change (YoY) | -1.30% |
| Shares Change (QoQ) | -2.30% |
| Owned by Insiders (%) | 0.90% |
| Owned by Institutions (%) | 107.99% |
| Float | 49.75M |
Valuation Ratios
The trailing PE ratio is 21.22 and the forward PE ratio is 14.41. Haemonetics's PEG ratio is 1.14.
| PE Ratio | 21.22 |
| Forward PE | 14.41 |
| PS Ratio | 2.60 |
| Forward PS | 2.61 |
| PB Ratio | 4.21 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 24.77 |
| P/OCF Ratio | 19.41 |
| PEG Ratio | 1.14 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 12.72, with an EV/FCF ratio of 31.21.
| EV / Earnings | 26.52 |
| EV / Sales | 3.27 |
| EV / EBITDA | 12.72 |
| EV / EBIT | 19.00 |
| EV / FCF | 31.21 |
Financial Position
The company has a current ratio of 1.62, with a Debt / Equity ratio of 1.49.
| Current Ratio | 1.62 |
| Quick Ratio | 0.88 |
| Debt / Equity | 1.49 |
| Debt / EBITDA | 3.50 |
| Debt / FCF | 8.60 |
| Interest Coverage | 9.42 |
Financial Efficiency
Return on equity (ROE) is 18.83% and return on invested capital (ROIC) is 7.54%.
| Return on Equity (ROE) | 18.83% |
| Return on Assets (ROA) | 6.29% |
| Return on Invested Capital (ROIC) | 7.54% |
| Return on Capital Employed (ROCE) | 12.49% |
| Revenue Per Employee | $372,115 |
| Profits Per Employee | $45,852 |
| Employee Count | 3,657 |
| Asset Turnover | 0.59 |
| Inventory Turnover | 1.70 |
Taxes
In the past 12 months, Haemonetics has paid $44.39 million in taxes.
| Income Tax | 44.39M |
| Effective Tax Rate | 20.93% |
Stock Price Statistics
The stock price has decreased by -26.74% in the last 52 weeks. The beta is 0.32, so Haemonetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | -26.74% |
| 50-Day Moving Average | 63.29 |
| 200-Day Moving Average | 73.45 |
| Relative Strength Index (RSI) | 71.15 |
| Average Volume (20 Days) | 607,575 |
Short Selling Information
The latest short interest is 4.35 million, so 8.67% of the outstanding shares have been sold short.
| Short Interest | 4.35M |
| Short Previous Month | 4.53M |
| Short % of Shares Out | 8.67% |
| Short % of Float | 8.75% |
| Short Ratio (days to cover) | 6.18 |
Income Statement
In the last 12 months, Haemonetics had revenue of $1.36 billion and earned $167.68 million in profits. Earnings per share was $3.31.
| Revenue | 1.36B |
| Gross Profit | 781.75M |
| Operating Income | 233.98M |
| Pretax Income | 146.99M |
| Net Income | 167.68M |
| EBITDA | 349.56M |
| EBIT | 233.98M |
| Earnings Per Share (EPS) | $3.31 |
Full Income StatementBalance Sheet
The company has $306.76 million in cash and $1.22 billion in debt, giving a net cash position of -$918.03 million or -$18.27 per share.
| Cash & Cash Equivalents | 306.76M |
| Total Debt | 1.22B |
| Net Cash | -918.03M |
| Net Cash Per Share | -$18.27 |
| Equity (Book Value) | 820.84M |
| Book Value Per Share | 16.69 |
| Working Capital | 356.86M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $181.73 million and capital expenditures -$39.28 million, giving a free cash flow of $142.45 million.
| Operating Cash Flow | 181.73M |
| Capital Expenditures | -39.28M |
| Free Cash Flow | 142.45M |
| FCF Per Share | $2.84 |
Full Cash Flow StatementMargins
Gross margin is 57.45%, with operating and profit margins of 17.19% and 12.32%.
| Gross Margin | 57.45% |
| Operating Margin | 17.19% |
| Pretax Margin | 15.58% |
| Profit Margin | 12.32% |
| EBITDA Margin | 25.69% |
| EBIT Margin | 17.19% |
| FCF Margin | 10.47% |
Dividends & Yields
Haemonetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.30% |
| Shareholder Yield | 1.30% |
| Earnings Yield | 4.75% |
| FCF Yield | 4.04% |
Dividend DetailsAnalyst Forecast
The average price target for Haemonetics is $99.78, which is 42.08% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $99.78 |
| Price Target Difference | 42.08% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on December 3, 2012. It was a forward split with a ratio of 2:1.
| Last Split Date | Dec 3, 2012 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |